Risk of bleeding with oral anticoagulants: An updated systematic review and performance analysis of clinical prediction rules

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1191-1200

  Loewen, Peter ^a   Dahri, Karen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anticoagulants; Bleeding; Clinical prediction rules; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ASSESSMENT TOOL; CLINICAL PREDICTION RULE; DRUG EFFECT; DRUG SAFETY; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VALIDATION PROCESS; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; METHODOLOGY; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG MONITORING; HEMORRHAGE; HUMANS; RISK ASSESSMENT; WARFARIN;

EID: 80055079237     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1267-3     Document Type: Article

References (44)

1. Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S-198S (Pubitemid 351892967)
2. Connolly SJ, Ezekowitz MD, Yusuk S, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 361. 10.1056/NEJMoa0905561
3. Schulman S, Kearon C, Kakkar AK, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER). N Engl J Med 361. 10.1056/NEJMoa0906598
4. Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE). Lancet 370:949-956 (Pubitemid 47393577)
5. Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673-1680
6. Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807-815
7. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95 (3):315-328 (Pubitemid 23270290)
8. ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study. Am Heart J 159(3):340-347.e.1
9. Gasse C, Hollowell J, Meier CR et al (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94(3):537-543 (Pubitemid 41300849)
10. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689-2696 (Pubitemid 46842784)
11. Dahri K, Loewen P (2007) The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 98:980-987 (Pubitemid 350091126)
12. The Cochrane Library. Cochrane reviewers' handbook 5.0.2. 2009; available at http://www.cochrane-handbook.org. Accessed 12 December 2010
13. Liberati A, Altman DG, Tetzlaff D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W-65-W-94
14. Sportif III (2003) Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698
15. Sportif V (2005) Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293:690-698
16. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692-694 (Pubitemid 41647882)
17. Ingui BJ, Rogers MAM (2001) Searching for clinical prediction rules in Medline. J Am Med Inform Assoc 8(4):391-397 (Pubitemid 32641642)
18. Laupacis A, Sekar N, Stiell IG (1997) Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA 277(6):488-494 (Pubitemid 27074334)
19. McGinn TG, Guyatt GH, Wyer PC et al (2000) Users' guides to the medical literature XXII: how to use articles about clinical decision rules. JAMA 284(1):79-84 (Pubitemid 30445665)
20. Peirce JC, Cornell RG (1993) Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making 13(2):141-151 (Pubitemid 23113451)
21. Deeks JJ, Altman DG (2004) Diagnostic tests 4: likelihood ratios. BMJ 329(7458):168-169
22. Greenhalgh T (1997) How to read a paper: papers that report diagnostic or screening tests. BMJ 315:540-543 (Pubitemid 27359111)
23. Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1991) Clinical epidemiology-a basic science for clinical medicine. London, Little Brown 51-68
24. Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928-935 (Pubitemid 46294733)
25. Jaeschke R, Guyatt G, Sackett DL (1994) Users' guides to the medical literature: III. How to use an article about a diagnostic test: A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271(5):389-391
26. Jaeschke R, Guyatt GH, Sackett DL (1994) User's guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 271(9):703-707 (Pubitemid 24061707)
27. van der Meer FJM, Rosendaal FR, Vandenbroucke JP et al (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76(1):12-16 (Pubitemid 26254309)
28. Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 138(5):1093-1100
29. Lip GYH, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57:173-180
30. Airaksinen KEJ, Suurmunne H, Porela P et al (2010) Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol 106:175-179
31. Ruiz-Giminez N et al (2008) Predictive variables for major bleeding events in patients presenting with document acute venous thromboembolism: findings from the RIETE registry. Thromb Haemost 100:26-31
32. Wess ML, Schauer DP, Johnston JA et al (2007) Application of a decision support tool for anticoagulation in patients with nonvalvular atrial fibrillation. J Gen Intern Med 23(4):411-417
33. Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87(2):144-152 (Pubitemid 19201634)
34. Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91-99 (Pubitemid 28405230)
35. Aspinall SL, DeSanzo BE, Trilli LE et al (2005) Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 20(11):1008-1013 (Pubitemid 41726654)
36. Wells PS, Forgie MA, Simms M et al (2003) The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163(8):917-920 (Pubitemid 36519737)
37. Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke. JAMA 285:2864-2870
38. Ohman EM, Granger CB, Harrington RA, Lee KL (2000) Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 284:876-878 (Pubitemid 30643616)
39. Harrell E, Califf R, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543-2546 (Pubitemid 12155954)
40. Canadian Cardiovascular Society (2010) Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. Available at http://www. ccsguidelineprograms.ca/index.php?option=com-content&view=article&id= 111&Itemid=66. Accessed 12 December 2010
41. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369-2429. doi:10.1093/eurheartj/ehq278
42. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA (1994) Patient preferences for stroke outcomes. Stroke 25:1721-1725 (Pubitemid 24274961)
43. Devereaux PJ, Anderson DR, Gardner MJ et al (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 323:1218-1222
44. Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients. Thromb Haemost 102:268-278